Home » Clinical Trials » Mesothelioma
Clinical Trial Details
Research Study Summary
A clinical research study of Pemetrexed and Cisplatin for the treatment of Mesothelioma or Pleural Mesothelioma
Research Study Title
Phase II Study of Neo-adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Malignant Pleural Mesothelioma
Despite the best surgical efforts, complete removal of mesothelioma is possible in
approximately 30% of the patients. When surgical removal is complete, chemotherapy followed
by radiation therapy is recommended as an effort to improve control over the cancer and
survival. This combination of treatments is called TRIMODALITY therapy. Unfortunately, the
chances for the tumor coming back after TRIMODALITY therapy remains high. When surgical
removal is not complete or not possible, some patients may receive chemo and/or radiation
therapy to achieve control over the cancer, but the chances of tumor to growth again remains
high and the chances of long term survival remains low.
The combination of Pemetrexed (Alimta) with Cisplatin has been approved as one of the
standard chemotherapy drug combinations for the treatment in advanced Malignant Pleural
Mesothelioma, and there is likely a group of patients who may benefit and potentially be
cured by this therapy. In an effort to achieve a better chance of complete removal of the
cancer and long term survival, the investigators are interested in using this drug
combination of Pemetrexed + Cisplatin before surgery and offer radiation therapy after
To Learn more
Both Male and Female
Both Male and Female ages 18 Years and up
Histologically proven diagnosis of MPM stages I to III. Patients will be clinically
staged using the AJCC/UICC TNM staging criteria (see Protocol Appendix 2). Eligible
Patients must be M0.
Patients with T1, T2, and T3 disease (without cardiac involvement) are eligible.
T status can be established clinically and radiologically or at exploratory
thoracotomy without surgical resection.
Patients with N0, N1, or N2 disease are eligible.
Performance status of 0 to 2 on the ECOG performance status schedule. See protocol
No prior systemic chemotherapy. No prior intracavitary cytotoxic drugs or
immunomodulators, unless given for the purpose of chemical pleurodesis.
No previous surgical procedure for mesothelioma, with the exception of previous
chemical pleurodesis and biopsy.
No previous radiation therapy for mesothelioma, or to the thorax.
Patients must be judged to be suitable candidates for this therapy at the UHN by the
attending medical oncologist, thoracic surgeon, and radiation oncologist before
Estimated life expectancy of at least 12 weeks.
Adequate organ function including the following:
Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count
(ANC) ³1,500/uL , platelets ³100,000/uL, hemoglobin ³ 9g/dL
Hepatic: bilirubin £1.5 times institutional upper limit of normal, alkaline
phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) £3
times institutional upper limit of normal
Renal: Creatinine £1.5 times institutional upper limit of normal; or Creatinine
clearance ³50 mL/min/1.73 m² for patients with creatinine levels above
institutional normal upper limit level. Cockcrot and Gault formula Appendix 4.
Pulmonary function tests:
Predicted post-operative DLCO (ppoDLCO) of > 35%.
If the ppoDLCO is < /= 35%, then additional studies will be done to determine the
patient's ability to tolerate the resection. The surgeon will correlate these
results with the patient's clinical status and make a decision as to the feasibility
Female patients of childbearing potential must test negative for pregnancy at the
time of enrolment based on a serum pregnancy test. Male and female patients must
agree to use a reliable method of birth control during and for 3 months following the
last dose of radiation therapy.
Patients must sign an informed consent
Have received treatment within the last 30 days with a drug that has not received
regulatory approval for any indication at the time of study entry.
Have previously completed or withdrawn from this study or any other study
Pregnancy or breast-feeding.
Serious concomitant systemic disorders (e.g., active infection) that, in the opinion
of the investigator, would compromise the safety of the patient or compromise the
patient's ability to complete the study.
Second active primary malignancy except in situ carcinoma of the cervix, adequately
treated non-melanomatous carcinoma of the skin, low grade (Gleason score < 6)
localized adenocarcinoma of the prostate or other malignancy treated at least 2
years previously with no evidence of recurrence.
Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a
5-day period (8 day period for long-acting agents such as piroxicam).
Inability or unwillingness to take folic acid, vitamin B12 supplementation, or
Refusal to have any of the treatment in the protocol (chemotherapy, extrapleural
pneumonectomy, and radiation therapy).
Site Locations (1)
||University Health Network
Ron Feld, MD
Marc dePerrot, MD
John Cho, MD
NCT ID: NCT00895648
Date Last Changed: June 7, 2012
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.